The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 19 of the 79 sources its claims cite were checked for support.
Abstract
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 0 Not valid · 43 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“16S ribosomal RNA (rRNA)-based sequencing of gene amplicons and shotgun DNA sequencing of patient stool samples have identified subsets of bacteria more abundant in responding versus nonresponding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The patient-stool analysis and Fig. 4 caption (page unavailable in our copy) identify bacterial clusters with differing Bacteroides abundance, and the paper reports 16S rRNA gene-amplicon sequencing of feces. But the treatment-response comparison was between mice receiving stool from different patient clusters, not responding versus nonresponding patients; our copy also does not report shotgun DNA sequencing of patient stool. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The indexed passage labeled Abstract (page not supplied) reports 16S rRNA sequencing of mouse fecal samples and identifies Bifidobacterium as associated with stronger antitumor responses. It does not report shotgun DNA sequencing or a comparison of responding and nonresponding patients; a later passage proposes sequencing patient stool as future work. (LLM, conf=0.88)
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The supplied passages (labelled Abstract; page not provided) describe 16S rRNA gene amplicon sequencing and metagenomic shotgun sequencing of patient stool samples. They report bacterial species differentially enriched in responders and nonresponders, including eight more abundant in responders. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accordingly, B. fragilis and Burkholderia cepacia administered via gavage to mice reduced the severity of colitis induced by mAb to CTLA-4 (13,22).”
What the sources say
- Supportedcites [13] source
The passage labeled Abstract (discussion of Fig. 3A; page not provided) reports that reconstituting antibiotic-treated mice with a combination of B. fragilis and B. cepacia reduced histopathological signs of colitis induced by CTLA-4 blockade. The Fig. 3 caption describes oral gavage and assessment of colonic lesions in those mice. (LLM, conf=0.94)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Results section, “Members of Bacteroidetes phylum associated with resistance” (page unavailable), reports an association between Bacteroidetes abundance and resistance to colitis in melanoma patients. Our copy does not address whether gavage with B. fragilis and Burkholderia cepacia reduced colitis severity in mice; searches for both species and for mouse gavage found no such passage. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with metastatic melanoma treated with the checkpoint inhibitor ipilimumab (antibody to CTLA-4), the abundance of Bacteroidetes inversely correlated with the severity of colitis (22).”
What the sources say
- Supportedcites [22] source
The Results section (‘Members of Bacteroidetes phylum associated with resistance’; page not provided) says the authors stratified patients by inflammation severity and found Bacteroidetes more abundant in colitis-free patients. The Methods identify the patients as adults with metastatic melanoma who received ipilimumab. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a study performed in 541 patients with hematologic malignancies reported that the gut microbiome at diagnosis influenced the probability of relapse within 2 years after ASCT.”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Methods and Results (page not provided) describe 541 patients with hematologic malignancies and assess microbiota associations with relapse or disease progression over two years. But the study concerns allogeneic HCT, not ASCT; its main cohort had stool samples collected within three weeks after transplantation, not at diagnosis. The Discussion describes an association, not evidence that the microbiome caused or influenced relapse. (LLM, conf=0.90)
plainstates an associationn = 541- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
In the paper’s discussion of Fig. 4, stools from one patient microbiome cluster promoted colonization by immunogenic B. fragilis and B. thetaiotaomicron, and mice receiving those stools responded to CTLA-4 blockade. The passage does not establish that these bacteria were more abundant in patients who responded to treatment; the reported treatment responses were in recipient mice. It also does not support the sentence’s full list of bacteria. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The passage labeled Abstract reports that Enterococcus faecium and Collinsella aerofaciens were among eight species more abundant in responding patients. These support the immunogenic-bacteria portion of the cited sentence; the paper does not need to establish every organism listed alongside other citations. (LLM, conf=0.92)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The paper’s indexed text (labeled Abstract; page unavailable) reports that Alistipes correlated positively with TNF production and that giving A. shahii to mice restored a tumor-associated immune response. This supports an immunogenic role for Alistipes, but the study does not show that it—or the other named bacteria—was abundant in responding patients. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims · 2 with their cited sources checked
Create a free account to see all 67 claims and to verify the 60 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, immune checkpoint inhibitory (ICI) therapy and adoptive cell therapy using tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) can be influenced by the composition of the intestinal microbiota4,5.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, following the epidemiological demonstration of the negative effect of antibiotics on the efficacy of ICIs13,42,90, specific microbial taxa have been associated with response or resistance to ICIs across distinct cancer types26,38–40,42,91–100.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The gut microbiome and immuno-oncology
“immunotherapy through a combination of TLR9 antagonist and antibody to interleukin-10R (IL-10R) (11)”
§ The gut microbiome and immuno-oncology
“The immunizing effects of antibody to IL-10R + the TLR9 agonist CpG”
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
Self-citationRetractedGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Self-citationDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications
Wong, S. H., & Yu, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0209-8 · Cited by 1,331
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Self-citationThe microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Self-citationHuman gut microbiota/microbiome in health and diseases: a review
Gomaa, E. Z. (2020) · Antonie van Leeuwenhoek · doi:10.1007/s10482-020-01474-7 · Cited by 1,294
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145
The gut microbiome: Relationships with disease and opportunities for therapy
Durack, J., & Lynch, S. V. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180448 · Cited by 943
“Gut microbiota in cancer immunotherapy Recent evidence has emphasized the importance of enteric microbiota in modulating response to various forms of cancer immunotherapy (Roy and Trinchieri, 2017; Zitvogel et al., 2018).”
BackgroundSpatially organized multicellular immune hubs in human colorectal cancer
Pelka, K., Hofree, M., Chen, J. H., Sarkizova, S., Pirl, J. D., Jorgji, V., Bejnood, A., Dionne, D., Ge, W. H., Xu, K. H., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.003 · Cited by 874
The inflammatory pathogenesis of colorectal cancer
Schmitt, M., & Greten, F. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00534-x · Cited by 775
Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24331-1 · Cited by 771
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
“In fact, the aim of administering probiotics to cancer patients, principally Lactobacilli, is to re-populate the compromised patients’ gut microbiota, thus re-establishing the levels and functionality of the commensal bacteria, depleted after the treatments [189].”
BackgroundCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Self-citationAntibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans
Hagan, T., Cortese, M., Rouphael, N., Boudreau, C., Linde, C., Maddur, M. S., Das, J., Wang, H., Guthmiller, J., Zheng, N.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.010 · Cited by 572
“, 2017) and anti-PD1 cancer immunotherapy (Gopalakrishnan et al., 2018; Routy et al., 2018; Zitvogel et al., 2018).”
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Application of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533
“highlighted the intertwined relationship between the composition of the microbiota and antitumor immune responses in advanced-cancer bearers treated with immunotherapy (8, 34).”
BackgroundSelf-citationDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling
Shi, Y., Zheng, W., Yang, K., Harris, K. G., Ni, K., Xue, L., Lin, W., Chang, E. B., Weichselbaum, R. R., & Fu, Y.-X. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192282 · Cited by 409
“Oral administration of commensal bacterial as an antitumor strategy has attracted much attention recently (Gopalakrishnan et al., 2018; Matson et al., 2018; Sivan et al., 2015; Zitvogel et al., 2018).”
BackgroundRole of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M. R., Hosseini-Fard, S. R., Babolhavaeji, K., Khani Ali Akbari, S., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 394
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396
Self-citationMicrobiome and colorectal cancer: Roles in carcinogenesis and clinical potential
Saus, E., Iraola-Guzmán, S., Willis, J. R., Brunet-Vega, A., & Gabaldón, T. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.001 · Cited by 350
“It has been suggested that gut microbiota activate natural anticancer immune responses through three main mechanisms: microbial or tumoral antigens activate T-cell response which in turn may activate tumor-specific immune responses (Zitvogel et al., 2018).”
BackgroundPeng, Z., Cheng, S., Kou, Y., Wang, Z., Jin, R., Hu, H., Zhang, X., Gong, J.-F., Li, J., Lu, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1014 · Cited by 361
“Three categories of possible mechanisms have been proposed (47): (i) through the T-cell responses induced by microbial antigens, (ii) through the engagement of pattern recognition receptors, and (iii) through small molecules produced by microbial metabolism.”
BackgroundThe microbiome extends host evolutionary potential
Henry, L. P., Bruijning, M., Forsberg, S. K. G., & Ayroles, J. F. (2021) · Nature Communications · doi:10.1038/s41467-021-25315-x · Cited by 329
Fecal microbiota transplantation in cancer management: Current status and perspectives
Chen, D., Wu, J., Jin, D., Wang, B., & Cao, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32003 · Cited by 321
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
“…can interrogate many aspects of the immune microenvironment, the in vivo efficacy of immunotherapies is also influenced by extrinsic factors that even holistic TME systems cannot currently replicate, such as interactions with peripheral lymphoid tissues 223,224 and the gut microbiome 225–227 .”
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J., Antonia, S., Mok, T., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 303
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer
Qu, R., Zhang, Y., Ma, Y., Zhou, X., Sun, L., Jiang, C., Zhang, Z., & Fu, W. (2023) · Advanced Science · doi:10.1002/advs.202205563 · Cited by 297
Self-citationScott, A. J., Alexander, J. L., Merrifield, C. A., Cunningham, D., Jobin, C., Brown, R., Alverdy, J., O’Keefe, S. J., Gaskins, H. R., Teare, J., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318556 · Cited by 288
Han, K., Nam, J., Xu, J., Sun, X., Huang, X., Animasahun, O., Achreja, A., Jeon, J. H., Pursley, B., Kamada, N., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00749-2 · Cited by 287
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Potential Role of the Gut Microbiome In Colorectal Cancer Progression
Kim, J., & Lee, H. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.807648 · Cited by 259
“It is known that changes in the gut microbiota not only affect tumor immunotherapy, but also affect therapeutic toxicity (22).”
BackgroundWirbel, J., Zych, K., Essex, M., Karcher, N., Kartal, E., Salazar, G., Bork, P., Sunagawa, S., & Zeller, G. (2021) · Genome Biology · doi:10.1186/s13059-021-02306-1 · Cited by 269
Microbiome in Colorectal Cancer: How to Get from Meta-omics to Mechanism?
Ternes, D., Karta, J., Tsenkova, M., Wilmes, P., Haan, S., & Letellier, E. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.01.001 · Cited by 251
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Biasci, D., Smoragiewicz, M., Connell, C. M., Wang, Z., Gao, Y., Thaventhiran, J. E. D., Basu, B., Magiera, L., Johnson, T. I., Bax, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013644117 · Cited by 262
Tulkens, J., De Wever, O., & Hendrix, A. (2020) · Nature Protocols · doi:10.1038/s41596-019-0236-5 · Cited by 245
Biomarkers for immunotherapy response in head and neck cancer
Gavrielatou, N., Doumas, S., Economopoulou, P., Foukas, P. G., & Psyrri, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101977 · Cited by 256
Li, Z., Wang, Y., Liu, J., Rawding, P., Bu, J., Hong, S., & Hu, Q. (2021) · Advanced Materials · doi:10.1002/adma.202102580 · Cited by 244
A collection of bacterial isolates from the pig intestine reveals functional and taxonomic diversity
Wylensek, D., Hitch, T. C. A., Riedel, T., Afrizal, A., Kumar, N., Wortmann, E., Liu, T., Devendran, S., Lesker, T. R., Hernández, S. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19929-w · Cited by 230
Dysbiosis of the Gut Microbiome in Lung Cancer
Zhuang, H., Cheng, L., Wang, Y., Zhang, Y.-K., Zhao, M.-F., Liang, G.-D., Zhang, M.-C., Li, Y.-G., Zhao, J.-B., Gao, Y.-N., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00112 · Cited by 235
“Laurence Zitvogel of the Gustave Roussy Cancer Center showed that some cancer treatments rely on the gut microbiota to activate the immune system (Gopalakrishnan et al., 2018; Zitvogel et al., 2018).”
BackgroundTransgenic Mouse Models in Cancer Research
Lampreht Tratar, U., Horvat, S., & Cemazar, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00268 · Cited by 214
“To fully evaluate the interplay between immunotherapies and the microbiota, new mouse models are emerging, such as specific pathogen-free mice with defined commensal bacteria or preconditioned with antibiotics, or germ-free mice lacking commensal bacteria (116).”
BackgroundThe intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells
Liu, N.-N., Yi, C.-X., Wei, L.-Q., Zhou, J.-A., Jiang, T., Hu, C.-C., Wang, L., Wang, Y.-Y., Zou, Y., Zhao, Y.-K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.012 · Cited by 223
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 205
Exploiting bacteria for cancer immunotherapy
Kwon, S.-Y., Thi-Thu Ngo, H., Son, J., Hong, Y., & Min, J.-J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00908-9 · Cited by 201
“The human microbiota has important implications for tumorigenesis and cancer therapy and, although the gut microbiota has been the primary focus of research in these areas 6–8 , insights into the existence and pathological relevance of intratumoural microbiota are beginning to emerge 9–12 .”
Zhu, X., Li, K., Liu, G., Wu, R., Zhang, Y., Wang, S., Xu, M., Lu, L., & Li, P. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2249143 · Cited by 220
“The potential mechanisms by which gut microbiota mediate antitumor immunity are through the activation of specific T cell responses against microbial antigens, which either provide support for tumor-specific immune activation or may cross-react against tumorspecific antigens.(17,22,23) However, it is still not”
BackgroundEmerging role of bacterial extracellular vesicles in cancer
Chronopoulos, A., & Kalluri, R. (2020) · Oncogene · doi:10.1038/s41388-020-01509-3 · Cited by 213
Microbiota in Tumors: From Understanding to Application
Xie, Y., Xie, F., Zhou, X., Zhang, L., Yang, B., Huang, J., Wang, F., Yan, H., Zeng, L., Zhang, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202200470 · Cited by 209
Im, E.-J., Lee, C.-H., Moon, P.-G., Rangaswamy, G. G., Lee, B., Lee, J. M., Lee, J.-C., Jee, J.-G., Bae, J.-S., Kwon, T.-K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09387-4 · Cited by 208
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 206
Current Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
arcasHLA: high-resolution HLA typing from RNAseq
Orenbuch, R., Filip, I., Comito, D., Shaman, J., Pe’er, I., & Rabadan, R. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz474 · Cited by 201
“In recent years, aided by landmark developments in 16S rRNA sequencing, wholegenome shotgun metagenomic sequencing and total RNA sequencing, a whole body of work has begun to map out the critical importance of our microbiome in systemic immunity, development, homeostasis, disease and patient responses to immunotherapy…”
BackgroundDerosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citationAre Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel, J.-C., Crozat, K., Dalod, M., & Mattiuz, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00009 · Cited by 194
Hou, J., Zhang, H., Sun, B., & Karin, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.014 · Cited by 193
Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
“, 2019) Another key example of microbiota-xenobiotic interaction is the differential response to immunotherapy, in part attributable to an individual’s baseline gut microbiota, in a number of malignancies including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and hepatocellular car…”
BackgroundAkkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases
Effendi, R. M. R. A., Anshory, M., Kalim, H., Dwiyana, R. F., Suwarsa, O., Pardo, L. M., Nijsten, T. E. C., & Thio, H. B. (2022) · Microorganisms · doi:10.3390/microorganisms10122382 · Cited by 179
“Immunotherapy for cancer is greatly affected by gut microbiota [90].”
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
Commensal bacteria stimulate antitumor responses via T cell cross-reactivity
Bessell, C. A., Isser, A., Havel, J. J., Lee, S., Bell, D. R., Hickey, J. W., Chaisawangwong, W., Glick Bieler, J., Srivastava, R., Kuo, F., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135597 · Cited by 184
“Although the overall diversity of the microbiome has been linked to positive clinical responses in patients, identifying homologous antigens found in commensal bacteria relevant to specific patients’ tumors will require more extensive studies with potentially a more robust, larger array of antigens to stimulate the T…”
BackgroundYang, L., & Chen, J. (2022) · Microbiome · doi:10.1186/s40168-022-01320-0 · Cited by 187
“Gut microbiome has also been demonstrated to be predictive of the cancer treatment outcome, spurring enthusiasm among cancer researchers in pursuit of a new cancer treatment paradigm [5, 6].”
Quantifying and Understanding Well-to-Well Contamination in Microbiome Research
Minich, J. J., Sanders, J. G., Amir, A., Humphrey, G., Gilbert, J. A., & Knight, R. (2019) · mSystems · doi:10.1128/msystems.00186-19 · Cited by 182
Limeta, A., Ji, B., Levin, M., Gatto, F., & Nielsen, J. (2020) · JCI Insight · doi:10.1172/jci.insight.140940 · Cited by 185
“Microorganisms in our gut are continually interacting with the gut epithelial barrier, through direct interactions with the microorganisms themselves, or through the myriad of diverse compounds they produce when metabolizing our diet (10, 11).”
BackgroundS‐adenosylmethionine: A metabolite critical to the regulation of autophagy
Ouyang, Y., Wu, Q., Li, J., Sun, S., & Sun, S. (2020) · Cell Proliferation · doi:10.1111/cpr.12891 · Cited by 177
Nanomedicine-based tumor photothermal therapy synergized immunotherapy
Shang, T., Yu, X., Han, S., & Yang, B. (2020) · Biomaterials Science · doi:10.1039/d0bm01158d · Cited by 179
Predictable modulation of cancer treatment outcomes by the gut microbiota
(2020) · doi:10.1186/s40168-020-00811-2 · Cited by 175
P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
Lara, R., Adinolfi, E., Harwood, C. A., Philpott, M., Barden, J. A., Di Virgilio, F., & McNulty, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00793 · Cited by 169
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00784-1 · Cited by 172
“Accumulating evidence points to the capacity of the intestinal ecosystem, and more specifically specific health-associated bacteria commensals to dampen systemic inflammation [5, 6], to shape the innate and adaptive immune tonus [7–10], and reprogram the tumor microenvironment in tumor bearing mice [11, 12] and patien…”
BackgroundSelf-citationDrago, L. (2019) · Microorganisms · doi:10.3390/microorganisms7030066 · Cited by 171
“Synergistic effect with anti-cancer and immunological drugs for improving their kinetics properties Hypothesis/Studies in progress [50,51]”
BackgroundMicrobiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Self-citationNeoadjuvant immunotherapy for non–small cell lung cancer: State of the art
Kang, J., Zhang, C., & Zhong, W. (2021) · Cancer Communications · doi:10.1002/cac2.12153 · Cited by 160
“The gut microbiota, galectin-3, and the intensity of CD8 cell infiltration may be useful as predictive biomarkers [106].”
BackgroundModulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
“Although there is clear evidence that the microbiome has an immunostimulatory function, it also remains to be defined which and if individual bacteria, or rather bacterial communities, are responsible for this and whether direct stimulation of T cell receptors, engagement of pattern recognition receptors, or system me…”
BackgroundGrajeda-Iglesias, C., Durand, S., Daillère, R., Iribarren, K., Lemaitre, F., Derosa, L., Aprahamian, F., Bossut, N., Nirmalathasan, N., Madeo, F., et al. (2021) · Aging · doi:10.18632/aging.202739 · Cited by 161
Self-citationImmunotherapy for Malignant Glioma: Current Status and Future Directions
Wang, H., Xu, T., Huang, Q., Jin, W., & Chen, J. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.12.003 · Cited by 179
CD8+ T cell exhaustion and cancer immunotherapy
Wang, Q., Qin, Y., & Li, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216043 · Cited by 155
Hu, Y., Li, J., Ni, F., Yang, Z., Gui, X., Bao, Z., Zhao, H., Wei, G., Wang, Y., Zhang, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32960-3 · Cited by 164
“Several studies have reported that the differences in diversity and composition of the gut microbiome might in fl uence cancer immunotherapy response 18 – 21 .”
BackgroundWu, H., Leng, X., Liu, Q., Mao, T., Jiang, T., Liu, Y., Li, F., Cao, C., Fan, J., Chen, L., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2593 · Cited by 159
Colorectal cancer and gut microbiota studies in China
Wang, Z., Dan, W., Zhang, N., Fang, J., & Yang, Y. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2236364 · Cited by 170
“Substantial evidence shows that the gut microbiota is associated with the efficacy or adverse effects of anti-tumor treatments such as chemoradiotherapy and immunotherapy.(95) The gut microbiota is a potential biomarker to predict anti-tumor responses and adverse reactions.”
BackgroundBaxevanis, C. N., Fortis, S. P., & Perez, S. A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.018 · Cited by 167
Microbiome dysbiosis in lung cancer: from composition to therapy
Liu, N., Ma, Q., Ge, Y., Yi, C., Wei, L., Tan, J.-C., Chu, Q., Li, J., Zhang, P., & Wang, H. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00138-z · Cited by 156
Naidoo, C., Nyawo, G. R., Wu, B. G., Walzl, G., Warren, R. M., Segal, L. N., & Theron, G. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30501-0 · Cited by 154
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Kepp, O., Marabelle, A., Zitvogel, L., & Kroemer, G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0272-7 · Cited by 154
Self-citationIbrahim, A. A., Hugerth, L. W., Hases, L., Saxena, A., Seifert, M., Thomas, Q. A., Gustafsson, J.-Α., Engstrand, L. G., & Williams, C. (2018) · International Journal of Cancer · doi:10.1002/ijc.32037 · Cited by 151
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Self-citationMicrobiome evolution during host aging
Aleman, F., & Valenzano, D. R. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007727 · Cited by 148
Tongue coating microbiome as a potential biomarker for gastritis including precancerous cascade
Cui, J., Cui, H., Yang, M., Du, S., Li, J., Li, Y., Liu, L., Zhang, X., & Li, S. (2018) · Protein & Cell · doi:10.1007/s13238-018-0596-6 · Cited by 143
Lu, K., Dong, S., Wu, X., Jin, R., & Chen, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638148 · Cited by 159
The biological underpinnings of therapeutic resistance in pancreatic cancer
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 156
“The gut microbiome is a complex ecosystem in constant communication with its host and is vitally important for intestinal epithelial, energy, hormone, and immune cell homeostasis (Zitvogel et al. 2018).”
BackgroundBeyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Zhu, Z., Cai, J., Hou, W., Xu, K., Wu, X., Song, Y., Bai, C., Mo, Y., & Zhang, Z. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2166700 · Cited by 145
“As an antitumor strategy, oral administration of commensal bacteria has attracted much attention.(3,4,34) For example, oral administration of Bifidobacteria has been proven to have an antitumor effect.”
BackgroundRecent updates on cancer immunotherapy
Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 145
Beyond the tumour microenvironment
Laplane, L., Duluc, D., Bikfalvi, A., Larmonier, N., & Pradeu, T. (2019) · International Journal of Cancer · doi:10.1002/ijc.32343 · Cited by 151
“Initial correlational observations were then confirmed experimentally by using FMT from patients to mice.(61) This demonstrates the possibility of a longdistance impact on responses to anticancer treatment within the broader context of the TOE, which opens up important avenues for future research (Fig.”
BackgroundMethodInfluentialWilliams, J. B., Li, S., Higgs, E. F., Cabanov, A., Wang, X., Huang, H., & Gajewski, T. F. (2020) · Nature Communications · doi:10.1038/s41467-020-14290-4 · Cited by 146
Self-citationWan, M.-L., Wang, Y., Zeng, Z. R., Deng, B., Zhu, B., Cao, T., Li, Y., Xiao, J., Han, Q., & Wu, Q. (2020) · Bioscience Reports · doi:10.1042/bsr20200265 · Cited by 137
T lymphocytes in the intestinal mucosa: defense and tolerance
Ma, H., Tao, W., & Zhu, S. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0208-2 · Cited by 125
Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010116 · Cited by 127
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 129
Microbiota and prostate cancer
Rizzo, A., Santoni, M., Mollica, V., Fiorentino, M., Brandi, G., & Massari, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.007 · Cited by 130
Metadata
- Authors
- Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F.
- Affiliations
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Paris Cité (FR)
- University of Chicago (US)
- Corresponding author
- Zitvogel, Laurence
- Gajewski, Thomas F.
- Venue
- Science
- Published
- 2018-03-23
- Volume
- 359
- Issue
- 6382
- Pages
- 1366-1370
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2791926234
- Cited by
- 777
- References
- 74
- Citations by year
- 2026: 84 · 2025: 85 · 2024: 74 · 2023: 96 · 2022: 84 · 2021: 130 · 2020: 105 · 2019: 81 · 2018: 37
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Melanoma Research Alliance (CA210098)
- University of Chicago (T32 CA009594)
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Jounce Therapeutics
- Incyte
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Fondation Leducq
- National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
- Fondation pour la Recherche Médicale
- Government of Jiangsu Province
- Ligue Contre le Cancer
- Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
- Institut Universitaire de France
- Chinese Academy of Medical Sciences (2016‐I2M‐1‐005, (CAMS-I2M), 2017RC31008, 2017NL31004, 2016ZX310194)
- Institut National Du Cancer
- Institut Gustave-Roussy
- Recruitment Program of Global Experts
- Genentech
- University of Chicago Medicine
- National Key Research and Development Program of China (2017YFA0506200)
- Labex Immuno-Oncology
- Comprehensive Cancer Center, University of Chicago Medical Center (T32 CA009594)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, host-microbe interactions, precision medicine, microbiome-based diagnostics, microbiota-based therapy, cancer immunotherapy resistance
- MeSH terms
- Gastrointestinal Microbiome, Humans, Immune System, Immunotherapy, Neoplasms, Treatment Outcome, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.